Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer

Journal of Clinical Oncology

Volumn 33, Issue 36, 2015, Pages 4284-4292

  Catenacci, Daniel V T ^a   Junttila, Melissa R ^g   Karrison, Theodore ^a   Bahary, Nathan ⁱ   Horiba, Margit N ^j   Nattam, Sreenivasa R ^k   Marsh, Robert ^c   Wallace, James ^a,d   Kozloff, Mark ^a,d   Rajdev, Lakshmi ^l   Cohen, Deirdre ^m   Wade, James ^e   Sleckman, Bethany ⁿ   Lenz, Heinz Josef ^h   Stiff, Patrick ^b   Kumar, Pankaj ^f   Xu, Peng ^a   Henderson, Les ^a   Takebe, Naoko ^o   Salgia, Ravi ^a   Wang, Xi ^g   Stadler, Walter M ^a   De Sauvage, Frederic J ^g   Kindler, Hedy L ^a   more..

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d Ingalls Memorial Hospital   (United States)

^e Decatur Memorial Hospital   (United States)

^f Oncology/Hematology Associates   (United States)

^g GENENTECH INC   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^j UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^k Ft Wayne Medical Oncology Hematology   (United States)

^l MONTEFIORE MEDICAL CENTER   (United States)

^m NEW YORK UNIVERSITY   (United States)

ⁿ ST JOHN S MERCY MEDICAL CENTER   (United States)

^o NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GEMCITABINE; PLACEBO; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PYRIDINE DERIVATIVE; SHH PROTEIN, HUMAN; SONIC HEDGEHOG PROTEIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER MORTALITY; CAPILLARY DENSITY; CARCINOGENESIS; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LIQUID CHROMATOGRAPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TANDEM MASS SPECTROMETRY; THROMBOCYTE COUNT; TUMOR GROWTH; TUMOR LOCALIZATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADULT; AGED; ANILIDES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HEDGEHOG PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MICE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PANCREATIC NEOPLASMS; PYRIDINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84957580046     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.8719     Document Type: Article

References (54)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
3. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
4. Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med 369:1691-1703, 2013
5. Kindler HL, Niedzwiecki D, Hollis D, et al: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28:3617-3622, 2010
6. Van Cutsem E, Vervenne WL, Bennouna J, et al: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231-2237, 2009
7. Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28:3605-3610, 2010
8. Kindler HL, Ioka T, Richel DJ, et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. Lancet Oncol 12:256-262, 2011
9. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
10. Robarge KD, Brunton SA, Castanedo GM, et al: GDC-0449: A potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 19:5576-5581, 2009
11. Wong H, Chen JZ, Chou B, et al: Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic hedgehog signalling pathway inhibitor. Xenobiotica 39:850-861, 2009
12. Von Hoff DD, LoRusso PM, Rudin CM, et al: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164-1172, 2009
13. Rudin CM, Hann CL, Laterra J, et al: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361:1173-1178, 2009
14. Catenacci DV: Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 9:967-996, 2015
15. LoRusso PM, Rudin CM, Reddy JC, et al: Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clinical Cancer Res 17:2502-2511, 2011
16. Jimeno A, Weiss GJ, Miller WH Jr, et al: Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clinical Cancer Res 19:2766-2774, 2013
17. Hidalgo M, Maitra A: The hedgehog pathway and pancreatic cancer. N Engl J Med 361:2094-2096, 2009
18. Morris JP 4th, Wang SC, Hebrok M: KRAS, hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nature Rev Cancer 10:683-695, 2010
19. Xu FG, Ma QY, Wang Z: Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. Cancer Lett 283:119-124, 2009
20. Kelleher FC: Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis 32:445-451, 2011
21. Sandhiya S, Melvin G, Kumar SS, et al: The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother 4:4-7, 2013
22. Thayer SP, di Magliano MP, Heiser PW, et al: Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851-856, 2003
23. Prasad NB, Biankin AV, Fukushima N, et al: Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 65:1619-1626, 2005
24. Yauch RL, Gould SE, Scales SJ, et al: A paracrine requirement for hedgehog signalling in cancer. Nature 455:406-410, 2008
25. Bailey JM, Swanson BJ, Hamada T, et al: Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clinical Cancer Res 14:5995-6004, 2008
26. Tian H, Callahan CA, DuPree KJ, et al: Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A 106:4254-4259, 2009
27. Theunissen JW, de Sauvage FJ: Paracrine hedgehog signaling in cancer. Cancer Res 69:6007-6010, 2009
28. Walter K, Omura N, Hong SM, et al: Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clinical Cancer Res 16:1781-1789, 2010
29. Olive KP, Jacobetz MA, Davidson CJ, et al: Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457-1461, 2009
30. Tremblay MR, Lescarbeau A, Grogan MJ, et al: Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 52:4400-4418, 2009
31. Feldmann G, Fendrich V, McGovern K, et al: An orally bioavailable small-molecule inhibitor of hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 7:2725-2735, 2008
32. Feldmann G, Habbe N, Dhara S, et al: Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 57:1420-1430, 2008
33. Catenacci D, Bahary N, Horiba N, et al: Final analysis of a phase Ib/Randomized phase II study of Gemcitabine (G) plus Placebo (P) or Vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study. J Clin Oncol 31:245s, 2013 (suppl 15s; abstr 4012)
34. Rhim AD, Oberstein PE, Thomas DH, et al: Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25:735-747, 2014
35. Lee JJ, Perera RM, Wang H, et al: Stromal response to hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci U S A 111:E3091-E3100, 2014
36. Madden JI: Infinity reports update from phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer. http://www.businesswire.com/news/home/20120127005146/en/Infinity-Reports-Update-Phase-2-Study-Saridegib#.Vg2sAuGJMQM
37. Hingorani SR, Wang L, Multani AS, et al: Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469-483, 2005
38. Romer JT, Kimura H, Magdaleno S, et al: Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 6:229-240, 2004
39. Singh M, Lima A, Molina R, et al: Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 28:585-593, 2010
40. Hruban RH, Adsay NV, Albores-Saavedra J, et al: Pathology of genetically engineered mouse models of pancreatic exocrine cancer: Consensus report and recommendations. Cancer Res 66:95-106, 2006
41. Chen W, Tang T, Eastham-Anderson J, et al: Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proc Natl Acad Sci U S A 108:9589-9594, 2011
42. El-Zaatari M, Daignault S, Tessier A, et al: Plasma Shh levels reduced in pancreatic cancer patients. Pancreas 41:1019-1028, 2012
43. Kim EJ, Sahai V, Abel EV, et al: Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clinical Cancer Res 20:5937-5945, 2014
44. Miles KA: Functional computed tomography in oncology. Eur J Cancer 38:2079-2084, 2002
45. Abe H, Murakami T, Kubota M, et al: Quantitative tissue blood flow evaluation of pancreatic tumor: Comparison between xenon CT technique and perfusion CT technique based on deconvolution analysis. Radiat Med 23:364-370, 2005
46. Kandel S, Kloeters C, Meyer H, et al: Whole-organ perfusion of the pancreas using dynamic volume CT in patients with primary pancreas carcinoma: Acquisition technique, post-processing and initial results. Eur Radiol 19:2641-2646, 2009
47. Hattori Y, Gabata T, Matsui O, et al: Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: Correlation with angiogenesis and fibrosis. World J Gastroenterol 15:3114-3121, 2009
48. Stoker MG, Shearer M, O'Neill C: Growth inhibition of polyoma-transformed cells by contact with static normal fibroblasts. J Cell Sci 1:297-310, 1966
49. Dotto GP, Weinberg RA, Ariza A: Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc Natl Acad Sci U S A 85:6389-6393, 1988
50. Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335-348, 2005
51. Gould SE, Low JA, Marsters JC Jr, et al: Discovery and preclinical development of vismodegib. Expert Opin Drug Discov 9:969-984, 2014
52. Wang Y, Zhou Z, Walsh CT, et al: Selective translocation of intracellular Smoothened to the primary cilium in response to Hedgehog pathway modulation. Proc Natl Acad Sci U S A 106:2623-2628, 2009
53. Dijkgraaf GJ, Alicke B, Weinmann L, et al: Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 71:435-444, 2011
54. Jesus-Acosta A, O'Dwyer PJ, Ramanathan RK, et al: A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA). J Clin Oncol 32, 2014 (suppl 3; abstr 257)